Pliant Therapeutics financials
$1.080.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.6M | $9.7M | $7.6M | $41.8M |
| Gross profit | $0.00 | $0.00 | $1.6M | $9.7M | $7.6M | $41.8M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M | -$41.6M |
| Net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.3M | -$41.5M |
| Net margin | — | — | −10211.1% | −1273.3% | −1284.5% | −99.3% |
| Diluted EPS | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.95 |
| EBITDA | -$154.7M | -$226.2M | -$182.3M | -$125.4M | -$96.0M | -$40.3M |
| Operating cash flow | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M | -$37.3M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M | -$38.8M |
| Diluted shares | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M | 21.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.4M | $71.2M | $63.2M | $33.7M | $51.7M | $50.9M |
| Short-term investments | $145.5M | $284.5M | $431.0M | $297.5M | $148.9M | $226.0M |
| Total debt | $0.00 | $30.2M | $10.1M | $12.4M | $0.00 | $0.00 |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M | $295.5M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M | $12.5M |
| Shareholders' equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M | $283.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology